BERKELEY, CA and VANCOUVER, BC--(Marketwired - August 17, 2016) -
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX VENTURE:
BCTXF) is pleased to announce that Dr. Jarrod P. Holmes, a Board Certified Oncologist
and a leading expert in breast cancer vaccines at Annadel Medical Group
and St. Joseph Health-Sonoma County, will serve as the clinical trial's
principal investigator and will work closely with Cancer Insight to manage
the clinical and regulatory aspects of the trial on behalf of BriaCell.
The primary site will be in Santa Rosa, CA, within St. Joseph Health-Sonoma
County's Regional Cancer Care program, awarded for excellence in cancer
care. St. Joseph Health in Sonoma County will enroll the first patient
in the upcoming Phase I/IIa clinical trial with BriaVax™, the Company's
lead vaccine candidate for management of advanced breast cancer, and is
expected to serve as a key center for subsequent patients.
"We are impressed with Dr. Holmes' deep expertise in development
and management of breast cancer vaccine clinical trials, and we are honored
to have him as a principal investigator for the Phase I/IIa clinical trials
of BriaVax™," stated Dr. Charles Wiseman, Founder and Director
of BriaCell. "High quality patient care is a top priority for us.
We are extremely pleased to have St. Joseph Health, which is committed
to excellent cancer care, as our primary site for the clinical trials
of BriaVax™," Dr. Wiseman added.
"We are pleased to evaluate the safety and activity of BriaVax™,
a novel vaccine, in patients with advanced breast cancer whose disease
has progressed following one of the standard treatments for this cancer,"
stated Dr. Holmes. "Vaccines are used to both treat and prevent cancer
by targeting the immune system. BriaVax™ has shown to activate the
immune system of the patient and has reduced the tumor volume without
serious side effects in a preliminary clinical trial. It is our hope to
further confirm that BriaVax™ will activate the immune system of
the patients to destroy the cancer cells, while being less harmful to
normal tissues than other treatment options."
Dr. Holmes has served as collaborating investigator in many vaccine research
programs since 2006, specializing in breast cancer vaccines for the prevention
of breast cancer recurrence. He has been extensively published for his
vaccine work, and was awarded Fellow of the American College of Physicians
for his accomplishments in research and academics. Dr. Jarrod Holmes earned
his medical degree at Duke University School of Medicine and completed
his Residency in Internal Medicine at the Naval Medical Center in San
Diego. He completed a fellowship in Hematology/Oncology with the National
Capitol Consortium in Bethesda, Maryland, and conducted vaccine studies
in the Cancer Vaccine Development Lab.
With its wide network of award-winning facilities including acute care
hospitals, home health agencies, hospice care, outpatient services, skilled
nursing facilities, community clinics and physician groups, St. Joseph's
is one of the largest healthcare service providers in Northern California
awarded for excellent oncology care and treatment.
BriaVax™ is a whole-cell breast cancer vaccine genetically engineered
to release GM-CSF, a natural substance the body produces to activate the
immune system. Previously, a small Phase I study documented very prompt
and near complete regression of metastatic breast cancer deposits in the
breast, lung, soft tissue and even the brain. The upcoming open-label
Phase I/IIa study will evaluate BriaVax™ in up to 24 advanced breast
cancer patients. The dosing of patients is scheduled to begin in the fall
of 2016 and will be accompanied by co-development of BriaDx™, our
companion diagnostic test.
BriaCell is an immuno-oncology biotechnology company developing a more
targeted, less toxic approach to cancer management. BriaCell's mission
is to serve late-stage cancer patients with limited treatment options.
Immunotherapy has come to the forefront of the fight against cancer, harnessing
the body's own immune system in recognizing and selectively destroying
the cancer cells while sparing normal cells. Immunotherapy, in addition
to generally being more targeted than commonly used types of chemotherapy,
is also thought to be a strong type of approach aimed at preventing cancer
BriaVax™, the Company's lead product, is a genetically engineered
whole-cell vaccine derived from a human breast tumor cell line. It is
believed to activate the immune system to recognize and eliminate cancerous
cells by inducing tumor-directed T cell and potentially antibody responses.
The Company has already demonstrated encouraging clinical results, and
is intent on building upon these results to further advance BriaVax™
through additional FDA-approved clinical trials in order to help cancer
patients with limited therapeutic options. The results of two previous
FDA Phase I clinical trials (one with the precursor cell line not genetically
engineered to produce GM-CSF and one with BriaVax™) have been encouraging
in patients with advanced solid tumors. Most notably, one patient with
metastatic breast cancer responded to BriaVax™ with substantial
reduction in tumor burden including lung and brain metastases.
For more information on the previous clinical trials, please visit
http://briacell.com/novel-technology/clinical-trials/, and on BriaCell per se,
About St. Joseph Health-Sonoma County
St. Joseph Health in Sonoma County is a not-for-profit provider of integrated
health care, sponsored by the St. Joseph Health Ministry. Entities include
the 338-bed Santa Rosa Memorial Hospital (the region's Level II Trauma
Center), the 80-bed Petaluma Valley Hospital, Memorial Hospice, Hospice
of Petaluma, North County Hospice, St. Joseph Urgent Care centers, and
St. Joseph Home Care Network. The organization's more than 2,000 local
employees offer residents of California's North Coast a spectrum of
healthcare services. These include Family Birthing, Neonatal Intensive
Care, Pediatrics supported by on-site pediatric hospitalists 24/7, urgent
care, preventive care and health promotion, outpatient behavioral health
care, palliative care, rehabilitation, and community benefit programs. Visit
stjoesonoma.org to learn more.
About Annadel Medical Group:
Annadel Medical Group is the local physician organization which partners
with the St. Joseph Heritage Healthcare medical practice foundation and
St. Joseph Health. Physicians employed by the medical group provide outpatient
and hospital-based services at facilities operated by St. Joseph Health
throughout Sonoma County, including Petaluma Valley and Santa Rosa Memorial
hospitals. Annadel Medical Group formed in Santa Rosa in October 2008,
and has expanded to serve a broad range of patients, with growing primary
care and specialty bases in Sonoma County.
The TSX Venture Exchange Inc. has in no way passed upon the merits of the
Company has neither approved nor disapproved the contents of this press
release. Neither TSX Venture Exchange nor its Regulation Services Provider
(as that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.
The securities offered have not been, and will not be, registered under
the U.S. Securities Act or any U.S. state securities laws, and may not
be offered or sold in the United States absent registration or an applicable
exemption from the registration requirements of the U.S. Securities Act
and applicable U.S. state securities laws. This press release shall not
constitute an offer to sell or the solicitation of an offer to buy securities
in the United States, nor shall there be any sale of these securities
in any jurisdiction in which such offer, solicitation or sale would be unlawful.
Cautionary Note Regarding Forward-Looking Information
Except for the statements of historical fact, this news release contains
"forward-looking information" within the meaning of the applicable
Canadian securities legislation which involves known and unknown risks
relevant to the Company in particular and to the biotechnology and pharmaceutical
industries in general, uncertainties and other factors that may cause
actual events to differ materially from current expectation. These risks
are more fully described in the Company's public filings available at
www.sedar.com. Other forward-looking information in this news release includes but is
not limited to the intended use of proceeds of the brokered and non-brokered
private placements and other terms of the brokered and non-brokered private
Readers are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this press release. The
Company disclaims any intention or obligation, except to the extent required
by law, to update or revise any forward-looking statements, whether as
a result of new information, future events or otherwise.
For further information contact:
Ms. Farrah Dean
Manager, Corporate Development
BriaCell Therapeutics Corp.
820 Heinz Avenue
Berkeley, CA 94710